, /PRNewswire/ -- . (NASDAQ: ), a global healthcare company, today announced that as part of its ongoing Board refreshment efforts, Rogerio Vivaldi Coelho, M.D.
, has been appointed as the newest member of its Board of Directors. Dr. Vivaldi will serve as a member of the recently reestablished Science and Technology Committee of the Board of Directors.
"We are pleased to welcome Dr. Vivaldi to our Board of Directors," said , Chair of the Board, Viatris. "We believe his proven expertise and long track record of success will enhance the efforts of the Board across a range of areas, in particular with regards to our Science and Technology Committee.
We expect his insights to be greatly beneficial to the Company's growth strategy as we further invest in our pipeline by adding highly innovative products with meaningful patient impact." Dr. Vivaldi is the former President and Chief Executive Officer of Sigilon Therapeutics, Inc.
, a diabetes cell therapy company, where he also served as a member of the company's board of directors from 2018 until its acquisition by Eli Lilly and Company in 2023. Prior to joining Sigilon, Dr. Vivaldi served as Executive Vice President and Chief Global Therapeutics Officer at Bioverativ Inc.
, Chief Commercial Officer at Spark Therapeutics, and as Chief Executive Officer of Minerva Neurosciences, Inc. Earlier in his career, Dr. Vivaldi led Genzyme Corporation's rare disease business as President of both the rare disease business and the renal & endocrin.
